CMPX — Compass Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1738021 ·
Last close
$2.40
Market Cap
$432.21M
52W High
$2.52
52W Low
$1.85
ADV30
2,895,784
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -26,979,000 | -25,154,000 | 190,173,000 | 35,453,000 | 24,124,000 |
| Mar 2026 | 0 | — | -20,299,000 | -18,317,000 | 205,170,000 | 55,168,000 | 18,697,000 |
| Dec 2025 | 0 | — | -17,990,000 | -15,716,000 | 219,588,000 | 30,643,000 | 22,797,000 |
| Sep 2025 | 0 | — | -15,817,000 | -14,259,000 | 231,259,000 | 46,212,000 | 21,646,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-56,110,000
Investing CF
$-65,082,000
Financing CF
$133,789,000
CapEx
$-283,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.40
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-474,643,000
Inventory
—
Receivables
—
ST Investments
$144,426,000
EBIT TTM
$-81,085,000
Pretax Income TTM
$-73,446,000
Interest Exp TTM
—
Analysts
12
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -72,839,000 | -66,489,000 | 219,588,000 | 22,797,000 | — | -49,143,000 |
| Dec 2024 | 850,000 | -56,625,000 | -49,375,000 | 140,403,000 | 15,170,000 | — | -44,855,000 |
| Dec 2023 | 0 | -50,363,000 | -42,494,000 | 156,875,000 | 8,337,000 | — | -40,618,000 |
| Dec 2022 | 0 | -41,655,000 | -39,225,000 | 199,645,000 | 18,007,000 | — | -34,125,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.54
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EDIT | Editas Medicine, Inc. | $460.74M | $3.00 | — |
| OCGN | Ocugen, Inc. | $461.19M | $1.36 | — |
| LXEO | Lexeo Therapeutics, Inc. | $403.67M | $4.92 | — |
| XFOR | X4 Pharmaceuticals, Inc | $401.54M | $4.05 | — |
| FENC | FENNEC PHARMACEUTICALS INC. | $399.77M | $11.40 | — |
News headlines (Yahoo Finance, 1h cache)
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
2026-07-17 14:42 · Yahoo
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
2026-06-08 13:06 · Yahoo
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
2026-05-21 21:00 · Yahoo
Compass Therapeutics to Participate in Upcoming May Investor Events
2026-05-12 11:30 · Yahoo
Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)
2026-05-05 12:16 · Yahoo
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
2026-05-05 11:30 · Yahoo
Does Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline Re‑Rating Opportunity?
2026-04-29 11:04 · Yahoo
Compass Therapeutics Touts “Stunning” PFS Win in COMPANION-002 as Crossover Muddy OS Data
2026-04-27 20:42 · Yahoo
Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Path To Profitability
2026-04-26 12:28 · Yahoo
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
2026-04-24 20:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.